Lisa Sershon

发表

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

M. Benatar, M. Bromberg, M. Pasnoor, 2020, JAMA neurology.

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

Adam L. Comer, Robert G. Miller, S. Demeret, 2023, The Lancet Neurology.

The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.

B. Khatri, J. Berger, John F Kramer, 2015, Multiple sclerosis and related disorders.